Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29518172 | 1.00 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL15559156 | 1.00 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL15551748 | 1.00 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL2861047 | 0.97 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL27752474 | 0.97 | SLC5A2 (0.45) | SLC5A2SLC5A1 | |
| SCHEMBL2871797 | 0.88 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| Proline SCHEMBL23000712 | 0.88 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| Proline SCHEMBL18546649 | 0.88 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| Proline SCHEMBL22115662 | 0.88 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| Proline SCHEMBL22115665 | 0.88 | SLC5A2 (0.39) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197429-B1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-05-22 | — | — | EP | claimed |
| US-11896574-B2 | Treatment of metabolic disorders in feline animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-02-13 | — | — | US | claimed |
| EP-2981269-B9 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-12-06 | — | — | EP | claimed |
| EP-3862003-B1 | AN SGLT-2 INHIBITOR FOR USE IN THE TREATMENT OF A METABOLIC DISORDER IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-25 | — | — | EP | claimed |
| EP-4234012-A2 | SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-08-30 | — | — | EP | claimed |
| EP-2981269-B1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-08-09 | — | — | EP | claimed |
| EP-4166548-A1 | CRYSTALLINE MONOHYDRATE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(BETA-D-GLUCOPYRANOS-1-YL)-BENZENE AND L-PROLINE IN CRYSTAL WATER (1:1:1) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-04-19 | — | — | EP | claimed |
| EP-3021832-B9 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-03-15 | — | — | EP | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| US-11185590-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20120277149-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| US-20120196812-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| EP-2396005-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | Boehringer Ingelheim International GmbH (DE) | 2011-12-21 | — | — | EP | claimed |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | claimed |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | claimed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| WO-2010092123-A1 | SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETE MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
| US-7776830-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-17 | — | — | US | claimed |
| EP-2187879-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196812-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | DPP4, SLC5A1, DPP7 | SLC5A2 5/4885SLC5A1 2/4885 |
| US-11185590-B2 | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | SI, PIM1, PIM3 | SLC5A2 399/4885SLC5A1 298/4885 |
| US-20120277149-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | SLC5A1, SLC5A2, CPT1A | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885 |
| US-11896574-B2 | Treatment of metabolic disorders in feline animals | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.